Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1989 3
1991 2
1993 1
1994 6
1995 1
1996 3
1997 3
1998 2
1999 4
2000 5
2001 4
2002 10
2003 9
2004 14
2005 13
2006 14
2007 7
2008 3
2009 6
2010 14
2011 9
2012 13
2013 6
2014 9
2015 22
2016 27
2017 19
2018 21
2019 19
2020 14
2021 23
2022 18
2023 18
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

322 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"
Page 1
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Hallek M, Al-Sawaf O. Hallek M, et al. Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367. Am J Hematol. 2021. PMID: 34625994 Free article. Review.
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. ...DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal …
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. ...DIAGNOSIS …
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M. Hallek M. Am J Hematol. 2019 Nov;94(11):1266-1287. doi: 10.1002/ajh.25595. Epub 2019 Oct 4. Am J Hematol. 2019. PMID: 31364186 Free article. Review.
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. ...DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal …
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. ...DIAGNOSI …
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Sibaud V, et al. Am J Clin Dermatol. 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. Am J Clin Dermatol. 2020. PMID: 32613545 Review.
The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible …
The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocyt …
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. Wierda WG, et al. J Natl Compr Canc Netw. 2022 Jun;20(6):622-634. doi: 10.6004/jnccn.2022.0031. J Natl Compr Canc Netw. 2022. PMID: 35714675
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. ...These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to t …
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has s …
CLL update 2022: A continuing evolution in care.
Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. Kay NE, et al. Blood Rev. 2022 Jul;54:100930. doi: 10.1016/j.blre.2022.100930. Epub 2022 Jan 26. Blood Rev. 2022. PMID: 35151528 Review.
Chronic lymphocytic leukemia (CLL) is diagnosed by the presence of a specific immunophenotype of clonal B cells in the peripheral blood. ...Multiple phase 3 clinical trials show that continuous therapy with novel agents such as Bruton tyrosine kinase inhibito …
Chronic lymphocytic leukemia (CLL) is diagnosed by the presence of a specific immunophenotype of clonal B cells in the …
Ibrutinib.
Charalambous A, Schwarzbich MA, Witzens-Harig M. Charalambous A, et al. Recent Results Cancer Res. 2018;212:133-168. doi: 10.1007/978-3-319-91439-8_7. Recent Results Cancer Res. 2018. PMID: 30069629
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. ...In addition, there is emerging clinical data on its efficacy in ABC subtype diffuse large B-cell lymphoma, multiple myelom …
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. ...In …
CLL immunotoxins.
Frankel AE, Kreitman RJ. Frankel AE, et al. Leuk Res. 2005 Sep;29(9):985-6. doi: 10.1016/j.leukres.2005.02.008. Epub 2005 Mar 17. Leuk Res. 2005. PMID: 16038723
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). ...Remissions have occurred in s …
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy re …
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. Jones JA, et al. Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12. Lancet Oncol. 2018. PMID: 29246803 Free PMC article. Clinical Trial.
Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia. In this study, we assessed the activity and safety of venetoclax in patients with chro …
Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory …
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Siddiqi T, et al. Blood. 2022 Mar 24;139(12):1794-1806. doi: 10.1182/blood.2021011895. Blood. 2022. PMID: 34699592 Free PMC article. Clinical Trial.
Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). ...We report results of the phase 1 do …
Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chroni …
BH3 Mimetics in Hematologic Malignancies.
Klener P, Sovilj D, Renesova N, Andera L. Klener P, et al. Int J Mol Sci. 2021 Sep 21;22(18):10157. doi: 10.3390/ijms221810157. Int J Mol Sci. 2021. PMID: 34576319 Free PMC article. Review.
Hematologic malignancies (HM) comprise diverse cancers of lymphoid and myeloid origin, including lymphomas (approx. 40%), chronic lymphocytic leukemia (CLL, approx. 15%), multiple myeloma (MM, approx. 15%), acute myeloid leukemia (AML, approx. 10%), an …
Hematologic malignancies (HM) comprise diverse cancers of lymphoid and myeloid origin, including lymphomas (approx. 40%), chronic …
322 results